Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James D Chambers

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
Health Affairs Scholar|July 29, 2024
Biosimilar underutilization alone does not foretell a broken biologics marketFariel LaMountain, Molly T Beinfeld, William Wong, et al.
JAMA Network Open|February 6, 2026
Drug Prices, Rebates, and Health Plan Coverage RestrictionsMolly T Beinfeld, Fariel LaMountain, Glenn A Phillips, et al.
Pharmacoeconomics|October 26, 2021
Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?James D Chambers, Nikoletta M Margaretos, Daniel E Enright, et al.
Journal of Vascular Surgery|May 22, 2012
A primer on cost-effectiveness analyses for vascular surgeonsNeal R Barshes, James D Chambers, Scott B Cantor, et al.
JCO Oncology Practice|May 21, 2026
Trends in Utilization Management for Oncology Therapies Amongst US Commercial Health Plans: 2017-2024Julia A Rucker, Molly T Beinfeld, Daniel Enright, et al.
Journal of Neuromuscular Diseases|December 9, 2025
U.S. health plan coverage of Neuromuscular Disease Therapies: An assessment of policy availability and restrictionsA Alex Levine, Julia A Rucker, Alex Cockerham, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2025
Use of health technology assessments in specialty drug coverage decisions by US commercial health plansDaniel E Enright, Emma G van Duijnhoven, Daniel A Ollendorf, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 26, 2013
Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expendituresJames D Chambers, Joanne Lord, Joshua T Cohen, et al.
Applied Health Economics and Health Policy|September 3, 2024
Are Drug Novelty Characteristics Associated With Greater Health Benefits?A Alex Levine, Daniel E Enright, Katherine A Clifford, et al.
Health Affairs Scholar|December 1, 2025
The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savingsMolly T Beinfeld, Priyanka Ghule, Fariel LaMountain, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
Health Affairs Scholar|July 29, 2024
Biosimilar underutilization alone does not foretell a broken biologics marketFariel LaMountain, Molly T Beinfeld, William Wong, et al.
JAMA Network Open|February 6, 2026
Drug Prices, Rebates, and Health Plan Coverage RestrictionsMolly T Beinfeld, Fariel LaMountain, Glenn A Phillips, et al.
Pharmacoeconomics|October 26, 2021
Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?James D Chambers, Nikoletta M Margaretos, Daniel E Enright, et al.
Journal of Vascular Surgery|May 22, 2012
A primer on cost-effectiveness analyses for vascular surgeonsNeal R Barshes, James D Chambers, Scott B Cantor, et al.
JCO Oncology Practice|May 21, 2026
Trends in Utilization Management for Oncology Therapies Amongst US Commercial Health Plans: 2017-2024Julia A Rucker, Molly T Beinfeld, Daniel Enright, et al.
Journal of Neuromuscular Diseases|December 9, 2025
U.S. health plan coverage of Neuromuscular Disease Therapies: An assessment of policy availability and restrictionsA Alex Levine, Julia A Rucker, Alex Cockerham, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2025
Use of health technology assessments in specialty drug coverage decisions by US commercial health plansDaniel E Enright, Emma G van Duijnhoven, Daniel A Ollendorf, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 26, 2013
Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expendituresJames D Chambers, Joanne Lord, Joshua T Cohen, et al.
Applied Health Economics and Health Policy|September 3, 2024
Are Drug Novelty Characteristics Associated With Greater Health Benefits?A Alex Levine, Daniel E Enright, Katherine A Clifford, et al.
Health Affairs Scholar|December 1, 2025
The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savingsMolly T Beinfeld, Priyanka Ghule, Fariel LaMountain, et al.
Pageof 10